条件激活野生型IL2的WTX-124最大化了IL2的治疗指数,与"非阿尔法"突变蛋白不同
Christopher J Nirschl1, Kulandayan K Subramanian1, Heather R Brodkin1
1Werewolf Therapeutics Inc., Watertown, Massachusetts.
Cancer immunology research
|February 13, 2026
概括
高剂量介白素2 (HD IL2) 显示为癌症治疗的前景,但会导致严重的毒性. 使用瘤激活的野生型IL2 (WTX-124) 的新方法可以增强T细胞激活和抗瘤功效,同时提高耐受性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 高剂量介白素2 (HD IL2) 提供持久的癌症反应,但具有严重的毒性,如血管泄漏综合征 (VLS).
- 工程 IL2 变体 (非阿尔法突变蛋白) 避免了 VLS,但表现出其他毒性,缺乏可比的抗瘤活性.
- 改善IL2的治疗指数对于晚期癌症治疗至关重要.
研究的目的:
- 研究一种瘤激活的野生型IL2分子 (WTX-124) 以提高IL2的耐受性和有效性.
- 为了确定条件IL2激活是否可以克服当前IL2疗法的局限性.
- 在临床前模型中,比较WTX-124与非阿尔法IL2突变蛋白的活性.
主要方法:
- 利用小鼠模型来评估抗瘤疗效和T细胞激活.
- 评估了IL2与高亲和度IL2受体α子单元 (CD25) 的相互作用.
- 采用药理动力学受体占用 (PK/RO) 建模来分析IL2的分布和参与.
主要成果:
- 野生型IL2对CD25的激活对于最佳的CD8+T细胞激活和抗瘤作用至关重要.
- 野生型IL2在激活瘤透淋巴细胞 (TILs) 方面显示出明显高于非阿尔法IL2的强度.
- 与非阿尔法IL2s不同,WTX-124在TILs上实现了高受体占用率,并具有较低的外周淋巴细胞参与度.
结论:
- 通过瘤向条件激活野生型IL2是改善IL2治疗的可行策略.
- 在不牺牲抗瘤活性的情况下,WTX-124显示了提高IL2耐受性的潜力.
- 这种方法可能为晚期癌症提供更安全,更有效的基于IL2的免疫疗法.
更多相关视频
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 31, 2013
20.8K
12:09Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
Published on: February 28, 2019
10.9K
相关概念视频
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.